Mucopolysaccharideosis Type I: A case report

Khodabandeh, Farzaneh; Alishahi, Reyhane; Yahyavi Koochaksaraei, Fatemeh

Document Type : Case report

Authors

¹ Nursing and Midwifery Faculty, Department of Midwifery, North Khorasan University of Medical Sciences, Bojnurd, Iran

² medical siense

³ Babol University of Medical Sciences, Department of Midwifery, Mazandaran, Iran

Abstract

Background and Aim: Mucopolysaccharidosis type I (MPS I) is a rare and highly progressive autosomal recessive, genetically-metabolic disorder that results of the mutation in the gene responsible for the production of Alpha-L-Iduronidase enzyme, which ultimately leads to destruction and cell death of tissues. The patient is asymptomatic at the time of birth, but few months after birth, symptoms gradually appear in the person's phenotype. Respiratory, skeletal, neurological, cardiac, gastrointestinal and ocular disorders are obvious in these patients. The purpose of this study is reporting a case of MPS I.

Patient introduction: The patient is a 7 years old boy, repeatedly admitted to the Heshmatieh Hospital of Sabzevar University of Medical Sciences, due to a weak immune system, high fever, and complications of his MPS genetic disease. At 2.5 years old, MPS had been definitively diagnosed.

Conclusion: In this patient, almost all symptoms of the Hurler syndrome including third tonsil, hepatomegaly, splenomegaly, large skull, large tongue, ocular corneal opacity, and the presence of yellow spots in sclera, spinal deviation, Umbilical hernia, hearing loss and the stenosis of the mitral valve was seen. Unfortunately, due to the lack of definitive treatment, only 20% of the patients have a chance of survival and recovery. MPS usually leads in death before the age of 20.

Keywords

Main Subjects

genetics

References

[1]. Natowicz MR, Shosrt MP, Wang Y, et al. Clinical and biochemical manifestations of hyaluronidase deficiency. New Engl J Med. 1996;335:1029-33.

[2]. Roubicek M, Gehler J, Spranger J. The clinical spectrum of alpha-iduronidase deficiency. Am J Med Genet. 1985; 20: 471-81.

[3]. Kahrizi K. Clinical signs of Mucopolysaccharidosis. Genetics in the 3rd millennium. 2006; 4(1):723-7.

[4]. Santos S, López L, González L, Domínguez MJ. Hearing loss and airway problems in children with mucopolysaccharidoses. Acta Otorrinolaringologica (English Edition). 2011;62(6):411-7.

[5]. Collins L, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology. 1990;97:1445-9.

[6]. Cheema HA¹, Malik HS¹, Hashmi MA¹, Fayyaz Z¹, Mushtaq I¹, Shahzadi N¹. Mucopolysaccharidoses -Clinical Spectrum and Frequency of Different Types. 2017 Feb; 27(2):80-83

[7]. Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler synndrome). Acta Pediatr. 1995; 84:337-9.

[8]. Russell C, Hendson G, Jevon G, et al. Murine MPS I: Insights into the pathogenesis of Hurler syndrome. Clin Genet. 1998; 53:349-61.

[9]. Pastores GM, Arn P, Beck M, Clarke JTR, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Molecular genetics and metabolism. 2007; 91(1):37-47.

[10].Hugh-Jones K. Early diagnosis of mucopolysaccharidosis. (Letter) Lancet II. 1983:1300.

[11].Kresse H, von Figura K, Klein U, Glössl J, Paschke E, Pohlmann R. [50] Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods in enzymology. 1982; 83:559-72.

[12].Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. In Seminars in perinatology. 2015; 39(3):206-16.

[13].Peake RWA, Bodamer OA. Newborn Screening for Lysosomal Storage Disorders. J Pediatr Genet. 2017; 6(1): 51-60. Epub 02.12.2016. En.

[14].Scott HS, Ashton LJ, Eyre HJ, Baker E, Brooks DA, Callen DF, et al. Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16. 3. American journal of human genetics. 1990;47(5):802-7.

[15].Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications. Human mutation. 1995; 6(4):288-302.

[16].Martins AM, Dualibi AP, Norato D, Takata ET, Santos ES, Valadares ER, et al. Guidelines for the management of mucopolysaccharidosis type I. J Pediatr. 2009; 155(4):32-46.

[17].Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007; 90(2):171-80.

[18].Shafaghati Y. Diagnosis and Treatment of Mucopolysaccharidosis. Genetics in the 3rd millennium. 2006; 4(1):728-32.

[19].www.ncbi.nlm.nih.gov/pubmed/12196045

[20].Laraway S, Mercer J, Jameson E, Ashworth J, Hensman P, Jones SA. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis Type I. J Pediatr. 2016;178:219-26. e1.

[21].Arn P, Wraith JE, Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr. 2009; 154(6):859-64.

[22].Kiely BT, Kohler JL, Coletti HY, Poe MD, Escolar ML. Early disease progression of Hurler syndrome. Orphanet J Rare Dis. 2017; 12(1):32.

Journal of Sabzevar University of Medical Sciences

Mucopolysaccharideosis Type I: A case report

References

References

Volume 25, Issue 4
September and October 2018
Pages 518-527

Mucopolysaccharideosis Type I: A case report

References

References

Volume 25, Issue 4September and October 2018Pages 518-527

Volume 25, Issue 4
September and October 2018
Pages 518-527